Adaptive Biotechnologies

company

About

Adaptive Biotechnologies translates scale and precision of the adaptive immune system into products to diagnose and treat disease.

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$125M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2009
Number Of Employee
251 - 500
Operating Status
Active
Stock Symbol
nasdaq:ADPT
Legal Name
Adaptive Biotechnologies Corporation
Also Known As
Adaptive TCR

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.


It was founded in 2009 and headquartered in Seattle, Washington.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
12
$831.85M
Adaptive Biotechnologies has raised a total of $831.85M in funding over 2 rounds. Their latest funding was raised on Sep 12, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 12, 2022 Post-IPO Debt $125M 1 OrbiMed Detail
Mar 24, 2022 Post-IPO Equity 1 ARK Investment Management Detail
Jul 14, 2020 Post-IPO Equity Detail
Jun 26, 2019 IPO $300M Detail
Mar 5, 2018 Secondary Market 1 Detail

Investments

Number of Investments
Number of Lead Investments
2
0
Adaptive Biotechnologies has made 2 investments. Their most recent investment was on Dec 28, 2021, when Entropy raised $1.95M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 28, 2021 Entropy
Pre-seed $1.95M Blockchain
Oct 19, 2021 Element Finance
Series A $32M Blockchain

Investors

Number of Lead Investors
Number of Investors
5
8
Adaptive Biotechnologies is funded by 8 investors. OrbiMed and ARK Investment Management are the most recent investors.
Investor Name Lead Investor Funding Round
OrbiMed Yes Post-IPO Debt
ARK Investment Management Yes Post-IPO Equity
Matrix Capital Management Yes Series F
Viking Global Investors Yes Series D
EquityZen Secondary Market
Rock Springs Capital Series F
Senator Investment Group Series F
Tiger Management Corporation Series F

Employee Profiles

Number of Employee Profiles
36
Adaptive Biotechnologies has 36 current employee profiles, including Employee William Atienza
Employee
Executive
Executive
Executive
Board member

Acquisition

Adaptive Biotechnologies has acquired 1 organizations. Their most recent acquisition was Sequenta on Jan 7, 2015. They acquired Sequenta for 0.

Date Company Name
Industry Acquisition Type Price
Jan 7, 2015 Sequenta
Biotechnology acquisition Detail